After Raymond James and Cowen & Co. gave Editas Medicine Inc (NASDAQ: EDIT) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Editas Medicine Inc today and set a price target of $55. The company’s shares closed yesterday at $24.63.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 13.7% and a 52.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Editas Medicine Inc is a Strong Buy with an average price target of $46.33, which is an 88.1% upside from current levels. In a report issued on July 23, Raymond James also maintained a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.80 and a one-year low of $17.80. Currently, Editas Medicine Inc has an average volume of 689.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
